As Medicare stakeholders frantically lobby to get their reforms included in physician payment relief legislation, an equally heated, but less urgent, debate is percolating on the FDA front involving biogenerics. While it is highly unlikely Congress will pass a biogenerics bill this year, the prospect of an Obama presidency has big Pharma nervous an aggressive biogenerics bill may be in the...


